Key regions: Australia, Italy, France, South Korea, Brazil
Vaccines are an essential part of healthcare systems worldwide, and Northern Africa is no exception. With a growing population and increasing awareness of the importance of vaccination, the vaccines market in this region is developing rapidly.
Customer preferences: In Northern Africa, customer preferences for vaccines are largely driven by the need for disease prevention. The region has seen significant outbreaks of diseases such as measles, polio, and meningitis in recent years, which has led to increased demand for vaccines. Additionally, customers in this region tend to prioritize affordability and accessibility when it comes to healthcare.
Trends in the market: One of the most significant trends in the vaccines market in Northern Africa is the increasing availability of vaccines. Governments and international organizations have been working to improve access to vaccines in the region, which has led to increased vaccination rates. Another trend is the growing use of combination vaccines, which offer protection against multiple diseases in a single shot. This approach has been particularly successful in Northern Africa, where it has helped to streamline vaccination programs and improve overall coverage.
Local special circumstances: One of the unique challenges facing the vaccines market in Northern Africa is the prevalence of counterfeit vaccines. This is a significant issue in the region, as counterfeit vaccines can be ineffective or even harmful. To combat this problem, governments and healthcare organizations have been working to improve vaccine regulation and increase public awareness of the risks associated with counterfeit vaccines.
Underlying macroeconomic factors: The vaccines market in Northern Africa is influenced by a range of macroeconomic factors, including population growth, healthcare spending, and government policies. As the population in the region continues to grow, demand for vaccines is likely to increase. Additionally, government policies aimed at improving healthcare infrastructure and increasing access to vaccines are likely to drive growth in the market. However, economic instability and political unrest in some countries in the region may pose challenges to the growth of the vaccines market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
